Related Experiment Videos
Effect of Weight-based versus Absolute Norepinephrine Dosing on Mortality Risk in Obese Patients with Septic Shock:
Pedro D Wendel-Garcia1, Sebastian Morales2, Sascha David3
1Pedro D. Wendel-Garcia M.D., M.Sc.: Institute of Intensive Care Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Division of Cardiothoracic Anesthesia and Intensive Care Medicine, Department of Anesthesiology, General Intensive Care and Pain Medicine, Medical University of Vienna and Vienna General Hospital, Vienna, Austria.
Anesthesiology
|May 6, 2026
Summary
Weight-based norepinephrine dosing may underestimate septic shock mortality in obese patients. Absolute dosing provides a more consistent approach across body mass index categories, improving risk stratification.
Area of Science:
- Critical Care Medicine
- Pharmacology
- Obesity Research
Background:
- Norepinephrine dosing is crucial for septic shock management, influencing treatment decisions and mortality prediction.
- Weight-based dosing accuracy may be compromised by rising obesity rates.
- Body Mass Index (BMI) impact on norepinephrine dosing strategies needs evaluation.
Purpose of the Study:
- To assess how BMI affects the relationship between norepinephrine dosing strategies (absolute vs. weight-based) and mortality in septic shock patients.
- To compare the accuracy of weight-based and absolute norepinephrine dosing in predicting mortality across different BMI categories.
Main Methods:
- Retrospective analysis of six large, multi-country ICU datasets.
- Inclusion of over 10,000 septic shock patients.
- Non-parametric generalized additive models used to analyze dosing strategies adjusted for disease severity (SOFA score).
Main Results:
- Weight-based norepinephrine dosing significantly underestimated mortality in obese patients (BMI > 30 kg/m²), with a 14.5% mean difference in predicted mortality.
- At higher doses (>0.3 µg/kg/min), weight-based dosing led to underestimation, reaching up to 26% divergence at 1 µg/kg/min between BMIs of 20 and 50 kg/m².
- Absolute norepinephrine dosing showed no significant impact of BMI on mortality estimation (0.3% mean difference).
Conclusions:
- Weight-based norepinephrine dosing may lead to inaccurate risk stratification and clinical decision-making in obese septic shock patients.
- Absolute norepinephrine dosing offers a more reliable and consistent method for mortality estimation across diverse BMI ranges.
- The findings highlight the need to reconsider weight-based dosing protocols in the context of patient obesity.
Related Concept Videos
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...